Bradmer Initiates Enrollment for Phase III Glioblastoma Multiforme Trial
Posted on: Thursday, 24 July 2008, 12:01 CDT
Bradmer Pharmaceuticals has initiated enrollment in the Phase III Glass-Art trial evaluating Neuradiab, a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme.
The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), for patients diagnosed with primary glioblastoma mulitforme.
The randomized trial will enroll up to 760 patients at leading treatment centers across the US.
Alan Ezrin, president and CEO of Bradmer, said: "We look forward to bringing this investigational drug to patients via collaborative efforts with more than 30 US cancer centers that are participating in the Glass-Art trial."
Source: Datamonitor
Related Articles
- Bradmer Initiates Enrollment in Phase III GLASS-ART Trial in Primary Glioblastoma Multiforme
- Molecular Insight Initiates Phase IIa Azedra Trial in Neuroblastoma Patients
- Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial in Neuroblastoma Patients
- Speedel Announces Start of Spp635 Phase Iia Trial in Diabetic Patients
- Hospital Launches State of the Art Patient Tracking and Integrated Patient Data System
- Norwood Abbey Announces Phase II Clinical Trial in Cancer Patients Commences
- U.S. Phase III Aridol Trial Enrols First Patient
- Somaxon Pharmaceuticals, Inc. Initiates Second Phase III Clinical Trial of SILENOR(TM) -- Product Will Be Evaluated in Long-Term Trial of Elderly Patients With Primary Chronic Insomnia
- CVBT Announces It Will Begin U.S. FDA-Authorized Clinical Trials in Diabetic Patients With Open Wounds
- Predix Pharmaceuticals Announces Initiation of Phase Ib Clinical Trial in Alzheimer's Patients; Provides Initial Dose Study Update
User Comments (0)
RSS Feeds